Atrosab

Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated Apoptosis induction and IL-6 and IL-8 production. Atrosab reduces neurological deficits. Atrosab can be used for research of inflammatory disease. The recommend isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) [1][2][3].

Product Specifications

CAS Number

[1365659-05-7]

UNSPSC

12352203

Target

Apoptosis; TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/atrosab.html

Purity

99.94

Solubility

10 mM in DMSO

Smiles

[Atrosab]

Molecular Weight

(145.837 kDa)

References & Citations

[1]Zettlitz KA, et al. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs. 2010 Nov-Dec;2 (6) :639-47.|[2]Zettlitz KA, et al. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody.|[3]E. Guenzi, et al. FRI0231 Atrosab, a humanized antibody directed against tnf-receptor 1, hold great promises for the treatment of rheumatoid arthritis. Ann Rheum Dis. 2013 Jun 14; 72 (3) :A451.|[4]Williams SK, et al. Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis. Sci Rep. 2018 Sep 11;8 (1) :13628.